MDC CONNECTS 2021
Complex Medicines: 
Why? What? When? Opportunities and Challenges

11 May 2021  |  2 - 3PM BST

© Medicines Discovery Catapult 2021. All rights reserved. Read our Privacy Policy

Complex Medicines: Selection and Characterisation of the Lead
18 May 2021  |  2 - 3PM BST
Register >

What is the commercial opportunity? - David Cook (Blueberry Therapeutics)
Shaping the UK into an international leader for complex medicines - Prof. Peter Simpson, CSO (MDC)
Complex medicines: The target landscape - Dr Duygu Yilmaz, Senior Scientist (MDC)

AGENDA

BOOK YOUR PLACE

ABOUT THE PRESENTERS

OTHER WEBINARS IN THE SERIES

Complex Medicines: Understanding Safety & Efficacy
15 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Understanding the Interplay with Biological Systems
25 May 2021  |  2 - 3PM BST
Register >

Complex Medicines: Ready for the Clinic/Scaling up for Success
22 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: A Glance at Novel Drug Delivery Systems
8 June 2021  |  2 - 3PM BST
Register >

Prof. Peter Simpson
Peter is Chief Scientific Officer for Medicines Discovery Catapult. His expert biology teams collaborate with universities and SMEs around the UK, generating innovative technology and assay methodologies to accelerate progress in therapeutic discovery. Peter has previously been Director of N8 Research Partnership, establishing multi-university research collaborations across the North of England and leading strategic engagement on innovation policy.

In 2020 at the start of the Covid pandemic, Peter led the establishment of the Alderley Park Lighthouse Lab, which now employs more than 600 staff and has delivered ~9 million Covid tests over the past year.

Previously, Peter has twenty years of experience in leading innovative drug discovery departments and programmes within major Pharmaceutical companies (Merck, AstraZeneca). He sits on multiple national and international advisory boards.

Dr Duygu Yilmaz
Dr Duygu Yilmaz, PhD, is a Senior Scientist in Target Engagement & Validation at Medicines Discovery Catapult, with over 5 years’ experience in drug research and development industry.

During her PhD, Duygu worked on functionalised liposomal drug delivery systems, which would release the drug payload in a highly sensitive manner in response to stimulus in the environment. She has experience in various other drug delivery systems including polymeric nanoparticles and cell penetrating peptides. At MDC, she is developing microscopy-based methods to study intracellular entry and trafficking of nanoparticles.

Dr Sarah Brockbank
Sarah Brockbank is Lead Scientist of External Drug Discovery at the Medicines Discovery Catapult. Here she supports SMEs develop and execute drug discovery projects and provides the project management of virtual preclinical programmes by connecting clients with expertise and capabilities.

 
Sarah has 30 years’ experience in the pharmaceutical industry. She is a molecular biologist with a focus mainly in target identification & validation and has worked across a broad range of disease areas. Sarah was a Drug Discovery Project Leader at AstraZeneca and she also has extensive experience in collaboration management and project management of large public-private consortia.

BACKGROUND

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.

In this first webinar, we will introduce the new and diverse field of complex medicines, the commercial opportunity presented and the current state of research in the UK community.

Dr David Cook
David Cook has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London and three years of academic post-doctoral experience. David has worked in the pharmaceutical industry for over 20 years. He worked in big pharma at AstraZeneca for more than 17 years in a wide variety of R&D roles both in the UK and the US. Whilst at AstraZeneca he worked on numerous drug projects from target selection through to supporting market products. He was also heavily involved in an in-depth analysis of AZ’s drug portfolio and understanding why projects fail and was the lead author on AZ’s “5Rs Paper” describing the learnings from this exercise. David joined Blueberry Therapeutics as Chief Scientific Officer at the start of 2014. In this role, he is responsible for leading the research activities of the business which are focused on developing new treatments for common dermatological diseases.